Neogenomics Inc Sample Contracts

Neogenomics Inc – NeoGenomics Reports 50% Revenue Growth to Record $102 Million in the Second Quarter (July 30th, 2019)

Fort Myers, Florida (July 30, 2019) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of cancer-focused genetics testing services, today announced second-quarter and first-half results for the period ended June 30, 2019.

Neogenomics Inc – CREDIT AGREEMENT dated as of June 27, 2019 by and among NEOGENOMICS LABORATORIES, INC.,as Borrower, NEOGENOMICS, INC., as Holdings, CERTAIN Subsidiaries OF HOLDINGSPARTY HERETO FROM TIME TO TIME,as Guarantors, THE LENDERS PARTY HERETO PNC BANK, NATIONAL ASSOCIATION, as Administrative Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Syndication Agent, REGIONS BANK, and HSBC BANK USA, NATIONAL ASSOCIATION, as Co-Documentation Agents PNC CAPITAL MARKETS LLC, and WELLS FARGO SECURITIES, LLC, as Joint Lead Arrangers, PNC CAPITAL MARKETS LLC, as Sole Bookrunner (June 28th, 2019)
Neogenomics Inc – NeoGenomics Announces New $250 Million Credit Agreement (June 28th, 2019)

Upon closing on June 27, 2019, NeoGenomics received the Initial Term Loan Facility principal in full along with access to the Revolving Credit Facility and utilized $100 million of proceeds to retire NeoGenomics’ prior outstanding term loan and revolving credit facility. NeoGenomics expects to utilize the remaining borrowing capacity to support inorganic growth opportunities and for general corporate purposes.

Neogenomics Inc – UNDERWRITING AGREEMENT (May 22nd, 2019)
Neogenomics Inc – UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (May 20th, 2019)

On December 10, 2018, NeoGenomics Laboratories, Inc. (“NeoGenomics Labs”), a wholly owned subsidiary of NeoGenomics, Inc. (the “Company” or “NeoGenomics”), completed the merger (the “Merger”) of Genesis Acquisition Holdings Corp. (“Genesis”) contemplated by the Merger Agreement dated October 23, 2018, which was filed as Exhibit 2.1 to the Current Report of the Company on Form 8-K, filed with the Securities and Exchange Commission on October 26, 2018. The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2018 of Genesis and its wholly-owned subsidiaries (referred herein as “Genoptix”), give effect to the Merger as if it had occurred on January 1, 2018, the first day of the fiscal year ended December 31, 2018. The pro forma condensed combined statement of operations for the three months ended March 31, 2019 has not been presented as the results of Genoptix are included in the results of NeoGenomics for the entire period and any pro forma adju

Neogenomics Inc – EMPLOYMENT AGREEMENT (May 8th, 2019)

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made this 14th day of April, 2017 by and between NeoGenomics, Inc. a Nevada corporation (“NeoGenomics” or the “Employer” and collectively with any entity that is wholly or partially owned by NeoGenomics, the “Company”), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and William Bonello (“Executive”), an individual who resides at xxxx.

Neogenomics Inc – Medical Services Agreement (May 8th, 2019)

This Medical Services Agreement (“Agreement”) is made and entered into on upon the date of last signature (“Effective Date”) by and between Lawrence Weiss, M.D., INC., a California professional corporation (“Medical Group”), with its mailing address at xxxxxxx and NEOGENOMICS LABORATORIES, INC., a Florida Corporation (together with its affiliates, “NeoGenomics”), with its mailing address at 12701 Commonwealth Dr., Suite 9, Fort Myers, FL 33913. NeoGenomics and Medical Group are each hereunder referred to individually as a “Party” and together as the “Parties.”

Neogenomics Inc – Steven C. Jones Re: Letter Agreement to Modify Provisions of Consulting Agreement Dear Steve: (May 8th, 2019)

This letter agreement (the “Letter Agreement”) serves to document our mutual agreement to make certain modifications to the Amended and Restated Consulting Agreement (the “Agreement”), dated November 4, 2016 by and between NeoGenomics, Inc. (the “Company”) and Steven C. Jones ("Executive”, and collectively with the Company, “we” or the “parties”) effective the date of this Letter Agreement (the “Letter Agreement Effective Date”). We have agreed that it is in the mutual best interest of the parties to modify the Agreement as follows.

Neogenomics Inc – NeoGenomics Reports 51% Revenue Growth to Record $96 Million in the First Quarter (April 30th, 2019)

Douglas M. VanOort, the Company’s Chairman and CEO, commented, “We are certainly pleased with our very strong first quarter financial results. Revenue growth in both our Clinical and Pharma services divisions exceeded expectations, and momentum accelerated throughout the quarter. The integration of Genoptix, while demanding, is progressing well and is on track. Profitability improved significantly as a result of better operating leverage and cost efficiency. We are excited with our excellent start to 2019, and by the opportunities for continued growth in revenue and profitability as the year unfolds.”

Neogenomics Inc – Becoming the World’s Leading Cancer Testing and Information Company OUR COMMON PURPOSE We save lives by improving patient care. OUR VISION By providing uncompromising quality, exceptional service and innovative solutions, we will be the world’s leading cancer testing and information company. OUR VALUES Quality, Integrity, Accountability, Teamwork, and Innovation Key 2018 Strategic Accomplishments Key 2018 Financial Highlights • Acquired Genoptix, adding critical scale • Performed approximately 750,000 clinical and complimentary capabilities to serve oncology tests for approximately 440,000 com (April 26th, 2019)
Neogenomics Inc – NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter (February 19th, 2019)

Douglas M. VanOort, the Company’s Chairman and CEO, commented, “Fourth quarter results were excellent, and a strong finish to a great year for our company. We reported record revenue and EBITDA for the quarter, with high-teens organic revenue growth for the second consecutive quarter and continuing improvements in profitability and cash flow.

Neogenomics Inc – UNDERWRITING AGREEMENT (December 12th, 2018)

NeoGenomics, Inc., a Nevada corporation (the “Company”) and GE Medical Systems Information Technologies, Inc. (the “Selling Shareholder”), confirm their respective agreements with Morgan Stanley & Co. LLC (the “Underwriter”) with respect to the sale by the Selling Shareholder and the purchase by the Underwriter of 10,835,145 shares of common stock, par value $0.001 per share, of the Company (“Common Stock”). The aforesaid 10,835,145 shares of Common Stock to be purchased by the Underwriter are herein called the “Securities.”

Neogenomics Inc – UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION (December 10th, 2018)

On December 10, 2018, NeoGenomics Laboratories, Inc. (“NeoGenomics Labs”), a wholly owned subsidiary of NeoGenomics, Inc. (the “Company” or “NeoGenomics”), completed the previously announced merger (the “Merger”) of Genesis Acquisition Holdings Corp. (“Genesis”) contemplated by the Merger Agreement dated October 23, 2018, which was filed as Exhibit 2.1 to the Current Report of the Company on Form 8-K, filed with the Securities and Exchange Commission on October 26, 2018. The unaudited pro forma condensed combined statements of operations for the year ended December 31, 2017 and for the nine months ended September 30, 2018 combine the historical consolidated statement of operations of Genoptix, Inc. (Predecessor) for the period from January 1, 2017 to February 28, 2017 and the historical consolidated statements of operations of Genesis and its wholly-owned subsidiaries (referred herein as “Genoptix”) for the period March 1, 2017 to December 31, 2017 and for the nine months ended Septemb

Neogenomics Inc – HISTORICAL CONSOLIDATED FINANCIAL INFORMATION (December 10th, 2018)

We have audited the accompanying consolidated balance sheet of Genesis Acquisition Holdings Corp. and subsidiaries (the "Successor Company”) as of December 31, 2017, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders' equity/deficit, and cash flows, for the period March 1, 2017 to December 31, 2017 and the related notes. In addition, we have audited the accompanying consolidated balance sheet of Genoptix, Inc. and subsidiaries (the “Predecessor Company") as of December 31, 2016, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders' equity/deficit, and cash flows, for the periods January 1, 2017 to February 28, 2017 and the year ended December 31, 2016, and the related notes (collectively referred to as the "consolidated financial statements"). Genesis Acquisition Holdings Corp. and Genoptix Inc. are collectively referred to as the "Company”.

Neogenomics Inc – NeoGenomics Reports 17% Revenue Growth to Record $69 Million (October 30th, 2018)

Consolidated Revenues for the third quarter of 2018 were $69.1 million, an increase of 17% over the same period in 2017. Clinical genetic test volume(1) increased by 14% year over year. Average revenue per clinical genetic test (“Revenue per Test”) increased by 3% to $320.

Neogenomics Inc – INDEX OF EXHIBITS Exhibit A Form of Certificate of Merger Exhibit B Form of Letter of Transmittal Exhibit C Form of Certificate of Incorporation of Surviving Company Exhibit D Form of Bylaws of Surviving Company Exhibit E Form of Joinder and Release Agreement by Indemnifying Fund Stockholders Exhibit F R&W Insurance Policy iv (October 26th, 2018)
Neogenomics Inc – NeoGenomics Signs Definitive Agreement to Acquire Genoptix (October 23rd, 2018)

Advances expansion into community oncology practices. Genoptix has well-established relationships with community oncology practices, a sales force and pathologists that are experienced in serving oncologists, and customized reports that are considered to be the gold standard among community oncologists. Oncology practices are an important, and under-penetrated, channel for promoting NeoGenomics’ capabilities in next-generation sequencing and liquid biopsy.

Neogenomics Inc – UNDERWRITING AGREEMENT (August 10th, 2018)
Neogenomics Inc – NeoGenomics Reports Record Revenue of $67.7 Million with 14% Increase in Clinical Volume Growth and 95% Increase in Pharma Services Backlog (July 24th, 2018)

Consolidated revenues for the second quarter of 2018 were $67.7 million, an increase of 8.8% over the same period in 2017. After adjusting 2017 results for the divestiture of PathLogic, revenue growth was 11.6%. Clinical genetic test volume(1) increased by 14.4% year over year. Average revenue per clinical genetic test (“Revenue per Test”) decreased by 3.6% to $318, primarily due to changes in Medicare reimbursement and regulation.

Neogenomics Inc – SECOND AMENDMENT TO CREDIT AGREEMENT (June 25th, 2018)

THIS SECOND AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) dated as of June 21, 2018, is by and among NEOGENOMICS LABORATORIES, INC., a Florida corporation (the “Borrower”), the Guarantors identified on the signature pages hereto, the Lenders identified on the signature pages hereto, and REGIONS BANK, as administrative agent (the “Administrative Agent”).

Neogenomics Inc – lives by improving patient care through communication, accuracy, reliability and efficiency. That commitment aligns closely with PPD’s mission and purpose to help its customers deliver life-changing therapies that improve health.” As a premier cancer diagnostics and pharma services company, NeoGenomics has a network of CAP-accredited (College of American Pathologists), CLIA-licensed (Clinical Laboratory Improvement Amendments) facilities across the U.S. About PPD PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycl (June 1st, 2018)
Neogenomics Inc – Supplemental Information Impact of ASU 606 Adoption (in thousands) (May 25th, 2018)
Neogenomics Inc – NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018 (May 1st, 2018)

Consolidated revenues for the first quarter of 2018 were $63.4 million, an increase of 10.4% over the same period in 2017. After adjusting 2017 results for the divestiture of PathLogic, revenue growth was 13.6%. Clinical genetic test volume(1) increased by 14.9% year over year. Average revenue per clinical genetic test (“Revenue per Test”) decreased by 3.4% to $319, primarily due to changes in Medicare reimbursement and regulation.

Neogenomics Inc – FIRST AMENDMENT TO CREDIT AGREEMENT (March 23rd, 2018)

THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) dated as of March 22, 2018, is by and among NEOGENOMICS LABORATORIES, INC., a Florida corporation (the “Borrower”), the Guarantors identified on the signature pages hereto, the Lenders identified on the signature pages hereto, and REGIONS BANK, as administrative agent (the “Administrative Agent”).

Neogenomics Inc – CONFIDENTIALITY, NON-SOLICITATION AND NON-COMPETE AGREEMENT (March 20th, 2018)

This Confidentiality, Non-Solicitation and Non-Compete Agreement (the “Agreement”) dated this 14th day of March, 2018 is entered into by and between Sharon Virag (“Employee”) and NeoGenomics, Laboratories Inc., a Florida corporation (“Employer” and collectively with NeoGenomics, Inc., a Nevada corporation (the “Parent Company”) and any entity that is wholly or partially owned by the Employer or the Parent Company or otherwise affiliated with the Parent Company, the “Company”). Hereinafter, each of the Employee or the Company maybe referred to as a “Party” and together be referred to as the “Parties”.

Neogenomics Inc – EMPLOYMENT AGREEMENT (March 20th, 2018)

THIS EMPLOYMENT AGREEMENT (“Agreement”) is made this 14th day of March, 2018 by and between NeoGenomics, Inc. a Nevada corporation (“NeoGenomics” or the “Employer” and collectively with any entity that is wholly or partially owned by NeoGenomics, the “Company”), located at 12701 Commonwealth Drive, Suite #5, Fort Myers, Florida 33913 and Sharon Virag (“Executive”), an individual who resides at XXXXXXX.

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (March 20th, 2018)

Douglas M. VanOort, Chairman and CEO, said, "We are delighted to welcome Sharon to our NeoGenomics team.  Her outstanding financial leadership skills and experience, coupled with her strong alignment with our NeoGenomics culture, will be invaluable to us as we continue to grow and develop our company. We are also very pleased to have George now serve as President of our fast-growing Pharma Services Division. He has an excellent understanding of operational and strategic imperatives for this business, and is uniquely suited to realize the Division’s potential."

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (February 21st, 2018)

Consolidated revenues for the fourth quarter of 2017 were $67.8 million, an increase of 12% over the same period in 2016.  After adjusting 2016 results for the divestiture of PathLogic, revenue growth was 15%.  Clinical genetic test volume(1) increased by almost 19% year over year.  Average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $338, primarily due to changes in test mix and reduced reimbursement levels for certain molecular tests.

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (October 25th, 2017)

Consolidated revenues for the third quarter of 2017 were $63.1 million, an increase of 4% over the same period last year.  Clinical genetic test volume(1) increased 17% year over year.  Average revenue per clinical genetic test (“Revenue per Test”) decreased by 11% to $342, primarily due to changes in test mix and a one-time $1.3 million revenue adjustment at quarter-end related to unbilled tests that were processed with insufficient specimen material.  As a result of its divestiture on August 1, 2017, PathLogic revenue decreased by $1.4 million, or 78%, from the same period last year.  The Company also estimates that Hurricanes Harvey and Irma depressed test volume by approximately 1.5% and revenue by approximately $1.0 million in the third quarter.

Neogenomics Inc – NEOGENOMICS, INC PRESS RELEASE (October 13th, 2017)

Clinical genetic test volume is expected to be approximately 162,500 tests, an increase of over 16% versus last year, and average-revenue-per-clinical-genetic test (“Revenue per Test”) is expected to be approximately $343, an 11% decrease from last year.  Average-cost-of-goods-sold per test (“Cost per Test”) is expected to be approximately $181, an 11% improvement from last year, and consolidated gross profit margin is expected to be 45.7%, an increase of 70 basis points versus last year.

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (July 25th, 2017)

Consolidated revenues for the second quarter were $66.1 million, an increase of 5% over the same period last year.  Clinical genetic test volume(1) increased 16% year over year, and average revenue per clinical genetic test (“Revenue per Test”) decreased by 8% to $355, primarily due to changes in test mix as a result of our leadership in the rapidly growing field of immuno-oncology testing, which currently has lower average pricing because of the large influx of PD-L1 testing.

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (April 26th, 2017)

Consolidated revenues for the first quarter were $61.7 million, an increase of 3% over the same period last year.  Clinical genetic test volume(1) increased 15% year over year, and average revenue per clinical genetic test (“Revenue per Test”) decreased by 9% to $354, primarily due to changes in test mix as a result of the rapid growth of lower priced immunohistochemistry (IHC) tests over the last year.

Neogenomics Inc – Transcript of NeoGenomics, Inc. (February 23rd, 2017)

Greetings and welcome to the NeoGenomics’ Fourth Quarter and Full Year 2016 Financial Results call. At this time, all participants are in a listen-only mode.  A question-and-answer session will follow the formal presentation. [Operator instructions].  As a reminder, this conference is being recorded.

Neogenomics Inc – NEOGENOMICS, INC. PRESS RELEASE (February 22nd, 2017)

Consolidated revenue for the fourth quarter was $60.5 million, an increase of 122% over the same period last year.  Clinical genetic test volume(1) increased 140% driven by the inclusion of Clarient’s results in the consolidated total.  Average revenue per clinical genetic test decreased by 10.5% year over year to $365, primarily due to the inclusion of Clarient’s lower average reimbursement rate per test in the combined test mix, but also due to the rapid growth of lower priced immunohistochemistry (IHC) and molecular tests.

Neogenomics Inc – NEOGENOMICS, INC. INDEMNIFICATION AGREEMENT (February 15th, 2017)

This Indemnification Agreement (this “Agreement”) is made and entered into as of the _____ day of ______________________, 20__ by and between NeoGenomics, Inc., a Nevada corporation (the “Corporation”), and ___________________________ (“Indemnitee”).